The Michael Jackson biopic "Michael" premiered Monday to an enthusiastic crowd of 3,000 attendees, including Jackson's family, who sang along to hits and wore fedoras and sequins. But reviews have been brutal—critics called it "disconnected from reality" and "frustratingly shallow." Despite the panning, box office expectations are stratospheric: analysts predict at least $70 million in its opening weekend.

The road to theaters was fraught. Major studios passed on the $150 million project, deeming Jackson too "radioactive" following the 2019 "Leaving Neverland" documentary. Lionsgate stepped in, with Graham King—the producer behind "Bohemian Rhapsody"—securing the deal. Production hit a major snag: after filming, lawyers discovered the estate was barred from mentioning Jordan Chandler, forcing $40 million to $50 million in reshoots to remove the third act entirely.

The financial stakes are enormous. Lionsgate needs just $150 million domestically to turn a profit, and analysts project $100 million in Japan alone. Universal paid $75 million for international rights. Given that "Bohemian Rhapsody" earned $911 million worldwide despite negative reviews, the studio is betting controversy won't hurt ticket sales—and early data suggests fan backlash may actually be driving demand.